XOMA Royalty (XOMA) Total Debt Growth (1y) (2011 - 2026)
XOMA Royalty (XOMA) Total Debt Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
5.94% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
- |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
- |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
XOMA Royalty |
5.52 Mn |
-60.56 Mn |
- |
-9.50% |
| Date | Value |
|---|
| Mar 31, 2026 |
-9.50% |
| Dec 31, 2025 |
-7.86% |
| Sep 30, 2025 |
-7.79% |
| Jun 30, 2025 |
-5.73% |
| Mar 31, 2025 |
-5.83% |
| Dec 31, 2024 |
-4.67% |
| Mar 31, 2021 |
-40.20% |
| Dec 31, 2020 |
-35.40% |
| Sep 30, 2020 |
-8.34% |
| Jun 30, 2020 |
19.48% |
| Mar 31, 2020 |
39.62% |
| Dec 31, 2019 |
43.59% |
| Sep 30, 2019 |
48.31% |
| Jun 30, 2019 |
75.20% |
| Mar 31, 2019 |
54.98% |
| Dec 31, 2018 |
54.26% |
| Sep 30, 2018 |
53.85% |
| Jun 30, 2018 |
-46.69% |
| Mar 31, 2018 |
-45.28% |
| Dec 31, 2017 |
-66.24% |
